A Phase I Study of IHL-305 (Irinotecan Liposome Injection) in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Yakult Honsha
- 31 Aug 2018 Biomarkers information updated
- 07 Apr 2009 Additional lead trial investigator identified as Keedy V as reported by Vanderbilt-Ingram Cancer Center.
- 07 Apr 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center 1024711)